Instead of Russia-Mans constant half truths and misrepresentations hoping it seems that no virus will work (typical Russian bot material), lets look to real science not conspiracy sites for legitimate information.
The Moderna test is just one of over 100 potential vaccine tests worldwide using different methods and pooling research to as quickly as possible find effective vaccines.
Moderna Test
The high dose cohort (250 mcg) group was discontinued but had higher number of anti-bodies from just one shot. The lower doze groups got booster shots and will be retested in about 3 months (per interview I say with two of the participants).
All volunteers produced antibodies by day 15 of the first injection.
The lowest group of 15 after the 2nd dose, after two weeks showed levels of binding antibodies (bind to the spikes which the virus uses to infect cells). that are the same level as in those that have recovered from the virus on their own.
The ten people with the medium dose (100 mg) had antibodies that significantly exceeded those of recovered patients. Only one person in this group had grade 3 erythema (redness) at the injection site.
3 of the participants in the high dose group had minor reactions that all resolved themselves with no serious reactions.
While everyone wants to speed up testing vs many years to develop a vaccine for similar viruses, they skipped the time required for the money test and did a mouse challenge test (giving them the flu after vaccine). Using the mRNA-1273 vaccine it prevented viral replication in the lungs of the mice.
One problem is that the liposomes needed is how long they will remain stable after thawing (they froze to -80C) so will have to test stability at different temperatures and storage methods. So may be an issue for overseas shipping.
Moderna has a published paper on lipids for mRNA delivery at PubMed Central PMCID: PMC5986714. It intends to publish soon the complete details of the current trial results.
Moderna has had years of research and funding regarding these long RNAs like the spike protein by transcribing the DNA template of the virus with T7 RNA polymerase. The doze or booster requirement is an issue since the mRNA chain in quite long - 5 kb and the modified uracils would probably decrease yield.
For Phase 2 testing with thousands, need to have them in an area with enough infection to see if it works "in the wild". Maybe get some volunteers from Brazil?
Jim Hartley says: "The spike protein we are making for serology is full length, I think, with the substitution of a phage trimerization domain to make the homotrimer more efficiently. And since Moderna injected a human only a couple of months after the sequence was published, I speculate there was not time to test smaller versions."
To speed up the process the Defense Department has lots of healthy young men and women who might volunteer for a challenge trial which would only take a few months vs much longer, maybe a year for a regular Phase 2 test. George Washington use the live smallpox variolation method on the Revolutionary Army.
What is the advantage of mRNA vs. more typical protein vaccine?
If you deliver the mRNA you can express the antigen on MCH 1, maybe on the cell surface. Moderna is going for that since they have the basic technology (mRNA + liposome), adapting it for the coronavirus is not a huge deal, and Moderna and Bancel are terminally hype-funding savvy.
On the more scientific side, I guess a mRNA vaccine theoretically could raise a more robust adaptive immune response with a single dose and without the need for adjuvants and booster vaccinations. As the foreign epitopes are expressed by cells, it could lead to a response that is weighed more heavily towards activation of cell cytotoxicity-based immunity, which could be more relevant for protection of viral infections than the predominantly humoral response you get with a standard protein/inactivated virus vaccine. But it’s all speculative – a successful RNA vaccine has yet to be developed.
Another advantage of mRNA vaccine over DNA vaccine is that it can’t possibly be inserted into the genome. It’s not just injecting some genetic material to get an immune response, but it’s getting the body to produce bountiful amounts of that genetic material itself, to become its own vaccine factory.
Conclusion of the Moderna potential vaccine: Results overall are limited but promising, and in other words, so far, so good. This is what you’d expect to see from a vaccine that works, and although it looks that way we don’t have enough information yet to quite say that it works, or how well. That is what Phase II and Phase III trials are for, and waiting for those results, from Moderna and from everyone else, will make the latter part of the summer and the fall interesting indeed.
Various sources including sciencemag not conspiracy sites.